公开(公告)号：WO2020178743A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051812

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  A61P37/04 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178741A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051810

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566 ,  A61K31/7088 ,  A61K31/713 ,  C07K14/7051 ,  C07K14/70596 ,  C07K2319/03 ,  C07K2319/70 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2740/13043 ,  C12N9/6494

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2017185169A8

公开(公告)日：2017-11-02

申请号：PCT/CA2017/000102

申请日：2017-04-27

Applicant: UNIVERSITY HEALTH NETWORK (UHN)

Inventor： HIRANO, Naoto ,  NAKATSUGAWA, Munehide ,  RAHMAN, Muhammed Aashiq ,  MURATA, Kenji

IPC: C07K14/74 ,  C12N15/12 ,  C12N5/10 ,  G01N33/53 ,  G01N33/569

Abstract: There is provided herein, the use of mammalian derived HLA class I molecule for in vitro peptide exchange. For example, there is provided a method of producing an HLA class I molecule complexed to a pre-selected peptide comprising: (a) providing a mammalian derived HLA class 1 molecule complexed to an existing peptide; (b) incubating, in vitro, the HLA class I molecule complexed to the existing peptide with the pre-selected peptide, wherein the pre-selected peptide is at a concentration sufficient to replace the existing peptide to produce the HLA class I molecule complexed to the pre-selected peptide; and the HLA class I molecule comprises a1, a1, a2, a3 and β2m domains.

公开(公告)号：WO2020178742A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051811

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  C12N5/12 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178740A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051809

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2023067577A1

公开(公告)日：2023-04-27

申请号：PCT/IB2022/060159

申请日：2022-10-21

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  LY, Dalam ,  SAIJO, Hiroshi ,  MATSUNAGA, Yukiko

IPC: C07K14/74 ,  A61K31/7088 ,  A61K38/17 ,  A61K38/46 ,  A61P35/00 ,  A61P37/02 ,  C12N15/10 ,  C12N15/12

Abstract: The present disclosure is directed to methods of modifying an HLA-binding pocket in an HLA molecule in a subject. Some aspects are directed to HLA molecules comprising a modified HLA-binding pocket, where the HLA molecule has increased affinity for a peptide, e.g., an antigen. Other aspects are directed to compositions comprising the same and methods of using the same.

公开(公告)号：WO2020178738A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051807

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K31/12 ,  A61K35/15 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/078 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020194195A1

公开(公告)日：2020-10-01

申请号：PCT/IB2020/052776

申请日：2020-03-24

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61K39/00 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/85 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a tyrosinase epitope, a MAGA-A1 epitope, a MART1 epitope, a MAGE-A3 epitope, or an SSX2 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178744A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051813

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding a gp100 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.

公开(公告)号：WO2020178739A1

公开(公告)日：2020-09-10

申请号：PCT/IB2020/051808

申请日：2020-03-03

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： HIRANO, Naoto ,  MURATA, Kenji ,  SASO, Kayoko

IPC: C12N15/62 ,  A61K31/675 ,  A61K31/7076 ,  A61K35/12 ,  A61K35/17 ,  A61K38/20 ,  A61P35/00 ,  C07F9/6584 ,  C07K14/705 ,  C07K14/725 ,  C07K14/74 ,  C07K19/00 ,  C12N15/113 ,  C12N15/12 ,  C12N15/55 ,  C12N15/867 ,  C12N5/0783 ,  C12N5/10 ,  G01N33/566

Abstract: The present disclosure is directed recombinant T cell receptors capable of binding an NY-ESO-1 epitope and nucleic acid molecules encoding the same. In some embodiments, the nucleic acid molecules further comprise a second nucleotide sequence, wherein the second nucleotide sequence or the polypeptide encoded by the second nucleotide sequence inhibits the expression of an endogenous TCR. Other aspects of the disclosure are directed to vectors comprising the nucleic acid molecule and cells comprising the recombinant TCR, the nucleic acid molecule, or the vector. Still other aspects of the disclosure are directed to methods of using the same. In some embodiments, the methods comprise treating a cancer in a subject in need thereof.